Topical
Total Trials
55
As Lead Sponsor
50
As Collaborator
5
Total Enrollment
10,194
NCT01731353
FungiScope - A Global Emerging Fungal Infection Registry
Phase: N/A
Role: Collaborator
Start: Mar 31, 2003
Completion: Dec 31, 2026
NCT00228982
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 31, 2004
Completion: Dec 31, 2005
NCT00124475
Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Start: Dec 31, 2004
Completion: Sep 30, 2007
NCT00124436
Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis
Start: Mar 31, 2005
Completion: Feb 28, 2007
NCT00210964
Ceftobiprole in Hospital Acquired Pneumonia
Start: Apr 30, 2005
Completion: May 31, 2007
NCT00210899
Start: Sep 30, 2005
Completion: Oct 31, 2006
NCT00229008
Start: Nov 30, 2005
NCT00309621
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Start: Apr 30, 2006
NCT00413439
Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy
Phase: Phase 2/3
Start: May 31, 2006
Completion: Jun 30, 2007
NCT00326287
Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
Start: Jun 30, 2006
Completion: Jul 31, 2007
NCT00413218
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Start: Mar 8, 2007
Completion: Mar 3, 2015
NCT00519675
Alitretinoin in the Treatment of Chronic Hand Eczema
Start: May 31, 2007
Completion: Not specified
NCT01030731
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
Phase: Phase 1
Completion: Aug 31, 2007
NCT01026740
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
Start: Jun 30, 2007
NCT01026558
A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
Start: Aug 31, 2007
Completion: Nov 30, 2007
NCT01026636
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
Completion: Apr 30, 2010
NCT00529282
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
Start: Oct 31, 2007
Completion: Jan 31, 2008
NCT00771719
Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia
Start: Oct 31, 2008
Completion: Nov 30, 2009
NCT00770978
Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU
Start: Nov 30, 2008
Completion: Sep 30, 2010
NCT00817063
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
Start: Jan 8, 2009
Completion: Apr 26, 2012
NCT00771524
Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone
Start: Apr 30, 2009
Completion: Feb 28, 2010
NCT00965042
Effect of Ceftobiprole on Human Intestinal Microflora
Completion: Jun 30, 2009
NCT01245140
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
Phase: Phase 2
Start: Apr 26, 2011
Completion: Apr 16, 2014
NCT01406171
Drug Interaction Study of Isavuconazole and Midazolam
Start: May 31, 2011
Completion: Jun 30, 2011
NCT01397929
An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
Phase: Phase 1/2
Start: Jun 30, 2011
Completion: Apr 30, 2016
NCT01752920
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Start: Dec 10, 2012
Completion: Aug 28, 2018
NCT02490800
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Start: May 20, 2015
Completion: Nov 24, 2022
NCT02956499
Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Start: May 24, 2016
Completion: Jul 3, 2017
NCT02895360
Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Start: Aug 24, 2016
Completion: Aug 7, 2020
NCT02957929
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
Start: Oct 31, 2016
Completion: Apr 20, 2017
NCT02527681
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
Start: Nov 22, 2016
Completion: Feb 25, 2020
NCT03230318
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Start: Sep 28, 2017
Completion: Oct 25, 2022
NCT03333005
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia
Start: Nov 27, 2017
Completion: Oct 26, 2018
NCT03439124
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
Completion: Mar 16, 2020
NCT03250299
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Start: Dec 15, 2017
Completion: Aug 24, 2022
NCT03137173
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Start: Feb 19, 2018
Completion: Apr 22, 2019
NCT04804059
A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males
Start: Aug 17, 2018
Completion: Sep 26, 2018
NCT03138733
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
Start: Aug 26, 2018
Completion: Mar 11, 2022
NCT03604705
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
Start: Oct 3, 2018
Completion: Jul 2, 2020
NCT04045613
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Start: Aug 2, 2019
Completion: Oct 4, 2022
NCT04098692
Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects
Start: Aug 8, 2019
Completion: Nov 18, 2019
NCT04166669
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
Start: Nov 12, 2019
Completion: Mar 3, 2020
NCT04148287
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Start: Dec 13, 2019
Completion: Dec 31, 2020
NCT04240886
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
Start: Jan 4, 2020
Completion: May 9, 2022
NCT04604132
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Start: Oct 6, 2020
Completion: Nov 21, 2022
NCT05491733
A Bioequivalence Study of APX001 High-load and Low-load Tablets
Start: Mar 2, 2021
Completion: Jun 23, 2021
NCT05582187
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
Start: Oct 31, 2022
Completion: Dec 31, 2025
NCT05856227
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Start: Aug 6, 2023
Completion: Dec 18, 2024
NCT05421858
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Start: Dec 11, 2024
Completion: Jan 30, 2028
NCT06808646
A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
Start: Jan 17, 2025
Completion: Feb 25, 2025
NCT06961708
A Study of Fosmanogepix in Healthy Adult Chinese Subjects
Start: Apr 14, 2025
Completion: Jul 15, 2025
NCT06925321
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
Start: Aug 26, 2025
Completion: Feb 29, 2028
Loading map...